Top Page
Peijia Medical Ltd.
(Frankfurt:9996)
Peijia Medical Ltd. (9996) vs. iShares MSCI Hong Kong ETF (EWH)
Peijia Medical Ltd. Business Overview & Revenue Model
Peijia Medical Ltd. Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 615.48M | 441.13M | 250.83M | 136.53M | 38.66M |
| Gross Profit | 433.62M | 325.37M | 176.20M | 95.65M | 25.22M |
| EBITDA | -192.93M | -348.52M | -359.90M | -546.54M | -190.87M |
| Net Income | -226.58M | -392.52M | -407.81M | -574.22M | -2.07B |
Balance Sheet | |||||
| Total Assets | 2.69B | 2.67B | 3.32B | 3.16B | 2.88B |
| Cash, Cash Equivalents and Short-Term Investments | 712.52M | 942.92M | 1.74B | 2.30B | 2.46B |
| Total Debt | 253.40M | 221.13M | 131.88M | 7.63M | 9.13M |
| Total Liabilities | 644.11M | 397.88M | 678.86M | 144.48M | 67.99M |
| Stockholders Equity | 2.03B | 2.27B | 2.64B | 3.02B | 2.81B |
Cash Flow | |||||
| Free Cash Flow | -285.29M | -899.67M | -506.61M | -506.11M | -206.35M |
| Operating Cash Flow | -5.18M | -583.49M | -376.20M | -436.37M | -181.10M |
| Investing Cash Flow | -140.38M | -386.29M | -463.28M | -424.75M | -12.48M |
| Financing Cash Flow | 10.38M | 85.11M | 117.44M | 741.98M | 2.34B |
Peijia Medical Ltd. Technical Analysis
Peijia Medical Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | €5.75B | ― | -10.43% | ― | 36.76% | 42.89% | |
51 Neutral | $7.35B | -0.20 | -44.53% | 2.35% | 30.18% | -1.17% | |
| ― | $3.09B | ― | -31.45% | ― | ― | ― | |
| ― | €808.27M | 58.79 | 3.22% | ― | ― | ― | |
67 Neutral | HK$8.58B | 43.12 | 4.39% | 0.97% | -32.05% | -54.47% | |
66 Neutral | HK$8.79B | 31.58 | 15.22% | 1.26% | 12.48% | 71.75% | |
51 Neutral | HK$3.09B | ― | -2.19% | ― | 5.32% | 89.43% |
Peijia Medical Ltd. Corporate Events
Peijia Medical Ltd. announced unaudited operating statistics for the first half of 2025, highlighting a revenue increase driven by market share gains in the TAVR sector and the introduction of premium products. The company expanded its TAVR portfolio into over 70 new hospitals, achieving significant growth in implantations. The launch of new neurointerventional products also contributed to robust performance, indicating strong market positioning and potential future growth.
The most recent analyst rating on (HK:9996) stock is a Buy with a HK$4.00 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.
Peijia Medical Ltd. has announced the successful completion of the first patient implant in the Global Clinical Study of its MonarQ TTVR® system, an innovative device designed to treat Tricuspid Regurgitation. This marks a significant milestone for the company, as it officially launches the global study and advances its pipeline development in this area, potentially impacting its market position and offering new treatment options for patients.
The most recent analyst rating on (HK:9996) stock is a Buy with a HK$4.00 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.
Peijia Medical Limited has outlined the terms of reference for its Nomination Committee, which was established to identify and recommend suitable candidates for the company’s board of directors. The committee, composed mainly of independent non-executive directors, is responsible for developing nomination guidelines and ensuring compliance with relevant laws and regulations. This move is expected to enhance the governance framework of Peijia Medical, potentially strengthening its industry position and stakeholder confidence.
The most recent analyst rating on (HK:9996) stock is a Buy with a HK$4.00 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.
Peijia Medical Ltd. has announced the composition of its board of directors and their roles within the company. The board comprises executive, non-executive, and independent non-executive directors, with specific members assigned to the audit, remuneration, and nomination committees. This announcement provides clarity on the governance structure of the company, which could impact its strategic decisions and stakeholder confidence.
The most recent analyst rating on (HK:9996) stock is a Buy with a HK$6.25 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.
Peijia Medical Ltd. announced that all resolutions proposed at its Annual General Meeting on May 27, 2025, were passed. These resolutions included the adoption of financial statements, re-election of directors, appointment of auditors, and granting of mandates to the board for share issuance and repurchase. The successful passage of these resolutions supports the company’s governance and operational strategies, potentially strengthening its market position and reassuring stakeholders of its stable management.
The most recent analyst rating on (HK:9996) stock is a Buy with a HK$4.00 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.
Peijia Medical Ltd. announced the grant of 1,439,400 share options to eligible employees under its Share Option Scheme. This initiative is designed to incentivize employees, with a vesting period spread over three years and performance targets tied to appraisals, potentially enhancing employee retention and aligning staff interests with company growth.
The most recent analyst rating on (HK:9996) stock is a Buy with a HK$4.00 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.